Protective Effects of Resveratrol on TNF-?-Induced Endothelial Cytotoxicity in Baboon Femoral Arterial Endothelial Cells.

Protective Effects of Resveratrol on TNF-?-Induced Endothelial Cytotoxicity in Baboon Femoral Arterial Endothelial Cells.

J Diabetes Res. 2013; 2013: 185172
Xiao J, Song J, Hodara V, Ford A, Wang XL, Shi Q, Chen L, Vandeberg JL

Endothelial injury induced by inflammatory factors plays a critical role in the pathogenesis of cardiovascular disease. Endothelial cell (EC) apoptosis, proliferation, migration, and cellular adhesion molecule (CAM) expression contribute to the development of atherosclerosis. We investigated the effects of resveratrol (0.1-100? ? M) on the proliferation, migration, and CAM expression of primary cultures of baboon arterial endothelial cells (BAECs). In addition, we tested its effects under normal conditions as well as under inflammatory conditions induced by tumour necrosis factor-? (TNF-?) administered either by cotreatment, pretreatment, or posttreatment. Immunocytochemistry, MTT, wound-healing, and flow cytometry assays were performed. The resveratrol treatment significantly enhanced BAEC proliferation and attenuated TNF-?-induced impairment of proliferation at the optimal doses of 1-50?µM. Resveratrol at a high dose (100? ? M) and TNF-? impaired BAEC migration, while low doses of resveratrol (1-50? ? M) attenuated TNF-?-induced impairment of BAEC migration. Moreover, resveratrol inhibited TNF-?-induced ICAM-1 and VCAM-1 expression. Taken together, our results suggest that the resveratrol protects BAECs after inflammatory stimulation as well as ameliorates inflammatory effects at low concentrations. Consequently, resveratrol should be considered as a candidate drug for the prevention and treatment of inflammatory vascular diseases. HubMed – drug


Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients.

World J Gastrointest Surg. 2013 Apr 27; 5(4): 115-22
Hanazaki K, Ichikawa K, Munekage M, Kitagawa H, Dabanaka K, Namikawa T

To evaluate the clinical usefulness of Daikenchuto (DKT) in hepatecomized patients.Twenty patients were enrolled with informed consent. Two patients were excluded because of cancelled operations. The remaining 18 patients were randomly chosen for treatment with DKT alone or combination therapy of DKT and lactulose (n = 9, each group). Data were prospectively collected. Primary end points were Visual Analogue Scale (VAS) score for abdominal bloating, total Gastrointestinal Symptoms Rating Scale (GSRS) score for abdominal symptoms, and GSRS score for abdominal bloating.The VAS score for abdominal bloating and total GSRS score for abdominal symptoms recovered to levels that were not significantly different to preoperative levels by 10 d postoperation. Combination therapy of DKT and lactulose was associated with a significantly poorer outcome in terms of VAS and GSRS scores for abdominal bloating, total GSRS score, and total daily calorie intake, when compared with DKT alone therapy.DKT is a potentially effective drug for postoperative management of hepatectomized patients, not only to ameliorate abdominal bloating, but also to promote nutritional support by increasing postoperative dietary intake. HubMed – drug


PPAR? agonist-induced alterations in ?6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway.

World J Hepatol. 2013 Apr 27; 5(4): 220-5
Saliani N, Darabi M, Yousefi B, Baradaran B, Khaniani MS, Darabi M, Shaaker M, Mehdizadeh A, Naji T, Hashemi M

To investigate the effect of MEK/ERK1/2 pathway on peroxisome proliferator-activated receptors (PPAR?) agonist-induced alterations in ?6-desaturase (?6D) and stearoyl-CoA desaturase 1 (SCD1) in hepatocellular carcinoma cell line HepG2.HepG2 cells cultured in RPMI-1640 were exposed to the commonly used ERK1/2 pathway inhibitor PD98059 and PPAR? agonist, pioglitazone. Total RNA was isolated and reverse transcribed from treated cells. Changes in gene expression and metabolites ratio, as activity index for ?6D and SCD1, were then determined using reverse transcription-polymerase chain reaction and gas liquid chromatography, respectively.The expression of both ?6D (P = 0.03) and SCD1 (P = 0.01) increased following PD98059 treatment, with a higher impact on SCD1 (24.5% vs 62.5%). Although pioglitazone increased the mRNA level (1.47 ± 0.10 vs 0.88 ± 0.02, P = 0.006) and activity index (1.40 ± 0.07 vs 0.79 ± 0.11, P < 0.001) of ?6D, no such changes have been observed for SCD1 activity index in pioglitazone-treated cells. SCD1 gene expression (+26.4%, P = 0.041) and activity index (+52.8%, P = 0.035) were significantly increased by MEK inhibition in the presence of pioglitazone, as compared with pioglitazone alone and control cells. However, the response of ?6D expression and activity index to pioglitazone was unaffected by incubation with PD98059.PPAR? and ERK1/2 signaling pathway affect differentially and may have inhibitory crosstalk effects on the genes expression of ?6D and SCD1, and subsequently on their enzymatic activities. HubMed – drug